Professional Documents
Culture Documents
EDITOR-IN-CHIEF
EMILIANO CORPAS
ASSOCIATE EDITORS
MARC R. BLACKMAN
RICARDO CORREA
S. MITCHELL HARMAN
ANTONIO RUIZ-TORRES
Elsevier
Radarweg 29, PO Box 211, 1000 AE Amsterdam, Netherlands
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
Copyright © 2021 Emiliano Corpas. Published by Elsevier Inc. All rights reserved.
The contributions of Marc R. Blackman and S. Mitchell Harman are in the public domain.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic
or mechanical, including photocopying, recording, or any information storage and retrieval system,
without permission in writing from the publisher. Details on how to seek permission, further
information about the Publisher’s permissions policies and our arrangements with organizations
such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our
website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the
Publisher (other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience
broaden our understanding, changes in research methods, professional practices, or medical
treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in
evaluating and using any information, methods, compounds, or experiments described herein.
In using such information or methods they should be mindful of their own safety and the safety
of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors,
assume any liability for any injury and/or damage to persons or property as a matter of products
liability, negligence or otherwise, or from any use or operation of any methods, products,
instructions, or ideas contained in the material herein.
vii
viii CONTRIBUTORS
Older persons often express disease differently than do younger adults; as a consequence, clinicians treating
elderly patients need to be aware that both symptoms and laboratory tests require special consideration. This is
so both to properly interpret clinical manifestations and to decide on an appropriate therapeutic approach.
Disregarding these differences may lead to significant medical errors with dire consequences.
Many of the physiological age-related changes in metabolism and body composition resemble those
typically seen with a variety of pathological disturbances in hormone balance. For example, there are decreases
in lean body and muscle mass and in bone density, increases in percent body fat and insulin resistance, and
reductions in resting metabolic rate, energy levels, and libido. These same phenomena are observed in young
adults with deficiencies of growth hormone (GH), sex steroid hormones, and thyroid hormone, as well as with
cortisol excess. To complicate matters further, such changes may also occur in the setting of a variety of
chronic diseases and malnutrition. Furthermore, aging is associated with an increased incidence and
prevalence of a host of illnesses, including endocrine disorders such as autoimmune hypo- and
hyperthyroidism, among others.
Conceptually, it is well understood that endocrine disorders fall into the category of pathophysiology, so
that any signs or symptoms of glandular dysfunction are generally explainable by pathophysiological analysis.
That is, as we age, physiological changes occur that can alter the pathophysiology and therefore the
clinical picture. The main aim of this monograph is to explain the characteristic pathological expressions of
hormonal alterations with advancing age. We hope that the reader will better understand and appreciate those
changes.
The chapters of this book have been divided according to specific endocrine systems and will provide the
reader, in an orderly fashion, with the most up-to-date published information regarding what is known about
how functions of various endocrine systems are altered during the aging process. It is also the intention of the
authors to provide perspective as to how such endocrine and metabolic changes may both be caused by, and
contribute to, the pathophysiology of aging.
The first chapters briefly explore the biological basis of human aging, noting that it is a process primarily
based on wear and tear that is modified by compensatory regulatory responses. This is where we differentiate
ourselves from inert matter, which ages by wearing, without regulatory compensation or repair. As an example,
if muscle tissue were to age just by cell attrition, individual prostration would be very premature. This is
because without deposition of collagen as a repairing and stabilizing element, and repair of myofibers by
mobilization of satellite cells, the gradual disappearance of myocyte tissue would soon lead to disorganization
of muscle components, with loss of movement, so that functional collapse would occur as an early
phenomenon. Therefore, the repair and stabilization of structures by collagen deposits and mobilization of stem
cells correspond to one regulatory and compensatory mechanism of aging.
Another example of age-related regulation is the rise of LDL-cholesterol, demand for which increases
with age, likely because cell membranes are subjected to the deleterious effects of free radicals that require
cholesterol for stabilization. However, hypercholesterolemia may be atherogenic, as evidenced by inherited
forms in the young. Hence, regulation itself may become pathogenic if it exceeds certain boundaries. In this
example, it is the physician’s task to evaluate the data on natural history of a phenomenon with an analysis
contrasting benefits for normal aging regulation with potential for damage (e.g., of hypercholesterolemia) as a
risk factor.
Thus, dyslipidemia represents an example of the difficulty in distinguishing normal from pathological, in
the metabolic-endocrine clinical presentation of an elderly patient. Other examples include type 2 diabetes and
osteoporosis, which increase with age, and therefore, with the aging process.
Endocrine activity moves to the beat of aging. We only need mention the frequent finding that in men,
testosterone production gradually declines with advancing age. Serum testosterone levels in the 5th decade
ix
x PREFACE
may be reduced by 50% from those exhibited in young adults, often reaching remarkably low levels in the
elderly. This phenomenon poses substantial difficulty in differentiating hypogonadism in the older male from
aging per se. Here again, the endocrinological challenge is to distinguish physiology from pathology.
Endocrine diseases can interfere with the aging process either by accentuating wear and tear, by
decreasing regulatory mechanisms, or both. For example, the typical restless hyperactivity of hyperthyroidism
may manifest as exhaustion and inactivity in older patients (apathetic hyperthyroidism), leading to a clinical
presentation similar to thyrotoxic myopathy. However, certain organs age almost exclusively by wear and tear.
Osteoarthritis is a disorder wherein continued operation and overload of the joints are the main determinants of
pathology. Hormonal influences are also involved in the process, either protecting joints against degeneration or
worsening its evolution. Androgens, on the one hand, and estrogens and thyroid hormones, on the other, can
influence the progression of such events. Osteoporosis is also a comparable state. Therefore, we must carefully
consider the association of endocrine diseases with osteoarthritic disorders, especially when hormone
replacement therapy is needed.
Other relevant issues are discussed in this book, including whether elderly men and women with
age-related reductions in sex hormones might or might not benefit from gender-appropriate hormone therapy,
whether there is a “somatopause” and if human GH treatment is harmful or beneficial in older patients with low
levels of GH secretion, and the problems of subclinical hyper- and hypothyroidism in elderly patients as
manifest by slightly low or high TSH levels. We believe that the authors provide the relevant data, pro and con,
vis-à-vis these important issues in a rational and balanced fashion. However, the sagacious clinician will
understand that, while such decisions should be data driven, they can only be made one patient at a time and in
accord with best practices and good clinical judgment.
Finally, we could not neglect discussions of benign prostatic hypertrophy and prostate cancer in this work.
Although those are not endocrine disorders, both show a clear endocrine interaction in the context of their close
relationship with aging.
In summary, this book presents endocrine physiology and pathophysiology in relation to the aging
process, paying special attention to manifestations of advanced age. We trust that the reader will appreciate
differences between the approaches of traditional clinical endocrinology and those that take into account the
changes of aging. The latter features must be increasingly considered as the patient transitions from young
adult to elderly. We will have achieved the goal to which we are committed if, henceforth, the reader considers
age as an essential factor in her/his diagnostic and endocrine management of older patients.
The selected format of this book is composed of chapters with comprehensive text as well as visual
content that have been developed as diagrams and graphic images. The book is aimed to become a friendly
and quick reference guide, suitable for the practicing clinicians treating elderly patients with endocrine
diseases and also for medical educators and trainees. We hope that you find it informative and useful.
Marc R. Blackman
Emiliano Corpas
Ricardo Correa
S. Mitchell Harman
Antonio Ruiz-Torres
ACKNOWLEDGMENTS
Editor
Dr. Emiliano Corpas wishes to thank his wife Trinidad and his daughter Sandra for their love,
unwavering support, and endless patience. He also states his appreciation to all staff members of
the Endocrinology Division of the Phoenix Veterans Administration Medical Center for their
professional collaboration, and expresses warm gratitude to Drs. Ricardo Correa, Carolina Chen,
and Karyne Vinales, and Darren Kristofic and Stephanie Kristofic RN, for their hospitality and
friendship. The participation, support, and input of so many colleagues and persons involved in this
book, especially from Elsevier, are very much appreciated. He would like to acknowledge as
well the brilliant contributions and advice of his long-term friends, colleagues, and authors,
Drs. Marc R. Blackman, S. Mitchell Harman, Álvaro Larrad-Jimenez, Franco Sánchez-Franco,
and Antonio Ruiz-Torres, and the paintings on the book covers created by his friend, Antonio
Heras Villanueva.
Associate Editors
Dr. Marc R. Blackman wishes to thank his wife, Linda, for her unstinting support and
endless patience during the writing and editing process. He would also like to thank his long-term
friends and colleagues, Dr. Emiliano Corpas, for his inspiring and tireless efforts in bringing this
book from concept to reality; Dr. S. Mitchell (Mitch) Harman, for sharing his deep knowledge and
wisdom; Drs. Ricardo Correa and Antonio Ruiz-Torres, for their writing and editorial expertise; all
the many coauthors, for their expert and informative contributions. He would also like to thank the
Elsevier staff for their exceptional professionalism and helpfulness; and all patients with age-
related endocrinological and metabolic disorders as well as the health providers who care for
them, to whom this book is dedicated.
Dr. Ricardo Correa first wants to thank God for giving him the strength to participate in this
amazing piece of art and medicine. Thanks to his wife Carolina and children (Matthew and
Elizabeth) for their support, cheering, and for the time that he was not able to spend with them.
Thanks to his mentor, Dr. Harman, for believing in him, and to Dr. Corpas for trusting him with this
big project and for becoming a friend and family member. Special thanks to Stephanie Kristofic,
RN, and Dr. Karyne Vinales for always being willing to help, and to all the endocrine fellows
(Ghada, Kelvin, Matthew, Mike, and Sonie) for serving as the inspiration for this book. Teaching the
next generation of endocrinologists and focusing on endocrinology in the elderly give us the
strength to continue.
Dr. S. Mitchell Harman would like to acknowledge the unswerving support of his wife
Carol who “kept the home fires burning” during the writing and editing of his chapters as well as
the insightful collaboration of his long-term personal and professional friend and coauthor,
Dr. Marc R. Blackman; the shared clinical and linguistic insights of the energetic and enthusiastic
Dr. Ricardo Correa; and most of all the vision and inspiration of his dear colleague, Professor
Emiliano Corpas, without whose lifetime dedication to the expansion of knowledge in
endocrinology this wonderful opus would never have seen the light of day.
Dr. Antonio Ruiz-Torres would mainly like to thank scientists Walter Beier (Leipzig), Gerhard
Hofecker (Vienna), and the late Bernhard Strehler (United States), whose basic investigation
contributed to a better understanding of the relationships between clinical manifestations and the
aging process, also in endocrinology. Dr. Ruiz-Torres’ contribution to this book is based on the
results and theories of those basic researchers. He also expresses his thanks to the associate
editors, especially to editor Dr. Emiliano Corpas for his idealistic engagement, dedication, and hard
work to make this book.
xi
BASIC PRINCIPLES OF THE AGING
PROCESS WITH ENDOCRINE AND
NUTRITIONAL IMPLICATIONS,
AGING AND DISEASE IN
CHAPTER 1
ENDOCRINOLOGY
Antonio Ruiz-Torres a, Emiliano Corpas b,c, Ricardo Correa d, Marc
R. Blackman e, and S. Mitchell Harman d
a
Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
b
HLA and Hospital Universitario de Guadalajara, Guadalajara, Spain
c
Faculty of Medicine, University of Alcalá, Madrid, Spain dDivision of
Endocrinology, Veterans Administration Medical Center, University of
Arizona College of Medicine, Phoenix, AZ, United States eWashington
DC Veterans Administration Medical Center, Georgetown University
School of Medicine, George Washington University School of Medicine,
Washington, DC, United States
CH APT ER OU TL INE
INTRODUCTION 2 PROBLEMS AND RISKS OF HORMONAL
What Is Aging? 2 TREATMENT OF THE AGING PROCESS 7
Senescent Cells and Senolysis 2 THE FALLACY OF HORMONAL
BASIC PRINCIPLES OF THE AGING PROCESS “REPLACEMENT" AS "ANTIAGING
WITH ENDOCRINE AND NUTRITIONAL MEDICINE" 9
IMPLICATION 3 AGING AND DISEASE IN
GROWTH VELOCITY AS DETERMINANT OF ENDOCRINOLOGY 9
LIFESPAN POTENTIAL 4 SUMMARY OF PHYSIOLOGICAL AGING AND
NUTRITIONAL INFLUENCE ON THE RATE OF ENDOCRINE SYSTEM 9
AGING 5 ENDOCRINOPATHIES IN ADVANCED AGE.
WEAR AND REGULATION: TWO MECHANISMS CHARACTERISTICS AND CONSIDERATIONS
THAT DETERMINE THE AGING PROCESS 5 FOR DIAGNOSIS AND THERAPY 10
Importance of Endocrine System 5 BIBLIOGRAPHICAL REFERENCES 11
Wear Regulation. Its Importance for the Course
of Aging 6
INTRODUCTION
WHAT IS AGING?
• Aging is due to entropy, the natural progression toward disorder, and randomness
in any system
• Everything ages: Both nonliving objects and living organisms
• Isolated systems can achieve a local reversal of entropy by using energy from outside
the system, but only at the cost of greater chaos in the larger environment
• Biological aging is:
• A progressive degradation of function and coordination of internal processes leading
to diminution of fitness of the organism
• The net outcome of the balance between processes of damage and self-repair/
regeneration
• Aging is heterogeneous
• Different species age at different rates
• Individuals of the same species age at different rates
• Systems within an individual age at different rates
• Specific theories regarding the aging process include:
• Accumulation of damage to cell components (proteins, lipid membranes, and DNA)
by free radicals
• Generated by internal metabolic processes
• Generated by external exposures (e.g., cigarette smoke)
• Opposed by antioxidant enzymes and (possibly) nutrients
• Deterioration of ability to carry out cell replacement and tissue repair
• Stem cell depletion or inactivation
• Immunosenescence (a special case of shift in cell populations)
• Telomere shortening leading to cell senescence
• Accumulation of senescent cells which produce toxic by-products (including
inflammatory cytokines) that have deleterious effects:
• Locally within tissues (paracrine)
• Systemically due to circulating factors (endocrine)
• Loss of systemic beneficial/growth factors that stimulate growth and repair
(some of which are classic hormones)
• All of the previously discussed may interact to produce organismal aging including
changes in function of the endocrine systems
SENESCENT CELLS AND SENOLYSIS
• Cellular senescence
• Senescent cells increase with aging in mice, monkeys, and humans and interventions
that increase lifespan in animals, including caloric restriction or mutations in the growth
hormone axis, are associated with decreased senescent cell abundance
• Cellular senescence is characterized by:
• Irreversible cell-cycle arrest accompanied by a senescent associated secretory
phenotype (SASP) (e.g., cytokines, tissue-damaging proteases, and others)
• Senescent cell antiapoptotic pathways (SCAPs) which make cells resistant to death
• All those mechanisms harm activity of local normal cells that display increased
senescent cell numbers
• Important markers of senescent cells include: p16INK4A, p21CIP1, and SASP factors
(e.g., IL-6, IL-8, monocyte chemoattractant protein-1, plasminogen-activated inhibitor-1),
and many others
BASIC PRINCIPLES OF THE AGING PROCESS WITH ENDOCRINE AND NUTRITIONAL IMPLICATIONS 3
• Senescent cells are associated and with age-related pathologies in animal models;
experimental studies have shown that young milieu is capable of protecting aging tissues
from cellular senescence
• Senolysis is based on targeting senescent cells to be eliminated by genetic or
pharmacological approaches
• Senolytic drugs are agents that selectively induce apoptosis of senescent cells acting on
SCAPs. Important features to consider:
• These agents exhibit a high degree of cell-type specificity
• Brief disruption of SCAPs can kill senescent cells. Thus senolytics could theoretically
be administered intermittently
• Proof-of-principle studies have showed that selective depletion or elimination of
senescent cells can prevent or delay chronic conditions in animal models as frailty,
cardiac dysfunction, vascular hyporeactivity and calcification, diabetes mellitus, liver
steatosis, osteoporosis, vertebral disk degeneration, pulmonary fibrosis, and radiation-
induced damage
• Early phase clinical trials are needed to know if chronic diseases as a group or one-at-a-
time might be prevented or delayed, as in animal models has been observed
• Cautions must be emphasized, particularly until clinical trials are completed and the
potential adverse effects of senolytic drugs are understood fully
(2)
(3)
(1)
(1) Growing stage, (2) maximum vitality stage, and (3) aging stage. The curve is represented as a model, using for k (growth
rate) 0.194, for μ 0.024, and for α 0.0095. (Concept of vitality according to W.Beier modified by A. Ruiz-Torres.)
The mathematical function vt ¼ exp (exp ( kt ) lnw0 βt ) expresses the periods of human
life in which parameters of growth (k), wear, and regulation (β) are involved (see previous panel).
β is the aging factor whose value β ¼ (μ α) results from the subtraction of the wear (μ) and
regulation (α). w0 is the ratio of maximum stature reached/stature at birth.
95
Maximum life expectancy
90
y = -15.2ln(x)+58.096
85 R 2 = 0.9582
80 Final Average
height lifespan
75
Primal dwarfism 102 74
70 Hypopituitarism 102 78
0.1 0.2 0.3 0.4
Growth constant
Normal (women) 169 78
Ruiz –Torres A. (datos no publicados) Normal (men) 182 82
(A) (B)
Graph A: Inverse relationship between growth velocity (k), on the abscissa, and average lifespan (T), on the ordinate, in a sample
of patients affected by dwarfism. T ¼ 1/β (1/k)lnw0; k ¼ (1/tmw)•ln(ln wt /ln wm)reached); tmw: age of maximum growth;
wt: stature at that age; wm: máximum stature (Unpublished data from author). Table B: Maximum stature and corresponding
life duration calculated according to T. GH deficiency or loss of GH receptors is associated with increased life span.
BASIC PRINCIPLES OF THE AGING PROCESS WITH ENDOCRINE AND NUTRITIONAL IMPLICATIONS 5
30
Lower economic level
20
P < 0.01
15
10
0
155.1 ± 0.8 P < 0.001 163.7 ± 0.2
Data from Holzerberger M et al.
Arch.Gerontol Geriatr 13:89-1001, 1991. (cm)
Survival data at 70 years of age, in relation to height recorded at the age of the military service in four provinces from Spain with
a higher poverty index compared with other five richer provinces, out of a total of fifty (data from 1858 to 1861 to military
service and 1910 in the respective surviving population).
Insulin
resistance
Functional adaptation
of beta cells
Glucose Type 2
Maintenance of intolerance diabetes
normoglycemia
Regulatory mechanisms of insulin resistance. Hyperinsulinemia may compensate wear caused by lower peripheral insulin
sensitivity (mainly at muscle). When secretory defects of insulin appear, also due to aging, which cannot overcome peripheral
resistance, older people are predisposed to develop glucose intolerance and type 2 diabetes.
This graph shows the theoretical behavior of vitality according to degree of regulation at a same wear. The steepest decline takes
place—that is, the highest rate of aging—when there is no regulation (1). Curve slope is markedly flattened, when regulation of wear
is 50% and there is a tendency toward longevity (2). If the wear is completely regulated, at 100% (3), it does not imply immortality
since this curve also shows a slope, although quite minor, but pointing toward an end which would be determined by entropy.
BASIC PRINCIPLES OF THE AGING PROCESS WITH ENDOCRINE AND NUTRITIONAL IMPLICATIONS 7
• Therefore graph shows the three components that determine the rate or speed of
aging: wear and its regulation and entropy1
• Testosterone administration:
• Parallels between effects of aging and those of hypogonadism2,3—changes in body
composition, sexual function, increased insulin resistance, depressive/cognitive
disorders—have led to administration of testosterone in late-onset hypogonadism
(see Chapters 10 and 11: Male Hypogonadism in Advanced Age)
• The potential adverse effects of testosterone,2,3,4 which may increase in advanced age,
include cardio-circulatory side effects, prostatic cancer or increased benign hypertrophy,
polycythemia, sleep apnea syndrome, or even liver damage with some formulations
• A favorable risk/benefit ratio of testosterone treatment in elderly men with clinical and
chemical hypogonadism5 has not been demonstrated (see Male Hypogonadism in Old Age)
• Testosterone replacement is recommended and approved only for use, in men with
organic hypogonadism that is hypothalamic-pituitary or testicular in origin, without
contraindications, and when adequate monitoring is done3
• GH administration:
• Interest started from an initial observation6 and subsequent studies of short
duration,7 which showed that GH administration to elderly subjects, to equalize serum
IGF-1 with that of young people, increased lean mass and reduced body fat mass. Less
constant results were the slight increase in muscle strength and maximum VO2 or an
increase in protein synthesis
• Adverse effects: After initial enthusiasm, studies described edema, arthralgias,
hyperglycemia, carpal tunnel syndrome, and gynecomastia, both in healthy elderly
1
Entropy, in this context, is the energy that exists in the system generated by its own disorder; it is a waste energy which is not
thermodynamically usable.
2
Snyder PJ. Approach to older men with low testosterone. Uptodate 2018.
3
Bhasin S et al. Testosterone Therapy. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103:
1715–1744, 2018.
4
Endocrine Society statement on the risk of cardiovascular events in men receiving testosterone therapy. www.endocrine.org.
5
Commitee of Institute of Medicine. National Academy Press, 2004.
6
Rudman D et al. N Engl J Med 323: 1–6, 1990.
7
Blackman MR et al. JAMA 288: 2282–2292, 2002.
8 BASIC PRINCIPLES OF THE AGING PROCESS WITH ENDOCRINE AND NUTRITIONAL IMPLICATIONS
subjects7,8 and in patients older than 60 years with adult onset of GH deficiency of organic
hypothalamic-pituitary etiology9
• Experimental studies have shown that mice lacking either GH secretion or GH receptors
live longer10,11 than wild type, which contradicts the idea of GH as an “antiaging” hormone
and supports the already described concept of growth acceleration as a determinant of life
potential
• Treatment with GH in adults is only indicated currently in selected patients with true
GH deficiency of pituitary-hypothalamic origin
• Menopausal hormone therapy (MHT):
• Therapy is indicated only for the treatment of menopausal symptoms, but not for
prevention of cardiovascular diseases, osteoporosis, or dementia12
• Use of MHT in late postmenopausal women is associated with an increase in the
following risks:
• In women >60 years (combined with medroxyprogesterone (MPA), continuous
therapy)13,14: Breast cancer, ovarian cancer, coronary vascular disease (CVD) events,
venous thrombosis and pulmonary embolism, stroke, and possibly dementia
• Estrogen given without MPA appears to protect against breast cancer and is neutral with
regard to CVD events
• Whether there is reduction in primary risk of coronary heart disease risk in early
menopause is controversial12,13,14,15
• It is well known that estrogen increases the risk of endometrial cancer when
administered alone
• MHT is associated with a lower risk of hip fractures and colorectal cancer, which
does not compensate for the aforementioned risks12,16
• MHT is a safe option for healthy, symptomatic women who are within 10 years
of menopause or younger than age 60 years and who do not have formal
contraindications12,16
• Estrogen-progestin therapy should be used for women with a uterus and only estrogen
for those without uterus12,16
• Thyroid function
• Since free T4 and total T3 do not change significantly with age, its application to
elderly people without thyroid disease has not aroused the interest seen for other
hormones (See Chapter 6: Physiology and Diseases of the Thyroid Gland in the Elderly.
Hypothyroidism. Hyperthyroidism)
• However, as previously mentioned, serum TSH < 0.1 mU/L (subclinical
hyperthyroidism), especially in advanced age, increases the risk of osteoporosis,
arrhythmias, ischemia, and/or myocardial hypertrophy
• Dehydroepiandrosterone and its sulfate
• Although concentrations decrease markedly with age,17 their administration to elderly
persons to restore circulating concentrations18 does not cause changes in insulin
sensitivity, nor in body composition, oxygen consumption, or muscle strength
8
Liu H et al. Ann Intern Med 146: 104–115, 2007.
9
Attanasio AF et al. J Clin Endocrinol Metab 87: 1600–1606, 2002.
10
Bartke A et al. Curr Top Dev Biol 63: 189–225, 2004.
11
Coschigano KT, et al. Endocrinology 141: 2608–2613, 2000.
12
Stuenkel et al. Menopause: ES Clinical Practice Guideline. J Clin Endocrinol Metab 100: 3975–4011, 2015.
13
Writing Group for the Women’s Health Initiative Investigators. JAMA 288: 321–333, 2002.
14
Manson JE et al. JAMA 310: 1353–1368, 2013.
15
Grady D. HERS study. JAMA 288: 49–57, 2002.
16
Martin KA, Barbieri RL. Menopausal hormone therapy: Benefits and risks. Uptodate 2018.
17
Harman SM. Endocrine changes with aging. Uptodate. Last updated: November 2016.
18
Nair KS et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl Med 355: 1647–1659, 2006.
BASIC PRINCIPLES OF THE AGING PROCESS WITH ENDOCRINE AND NUTRITIONAL IMPLICATIONS 9
• Menopause is the only well-defined, abrupt, and universal change which is a function
of age. It causes the most relevant deleterious clinical changes in bone and lipid
metabolism and in the vascular and genitourinary systems
• The following functions decline with age in most subjects: Secretory function of
GH-IGF1, male hypothalamic-pituitary-gonadal axis, and adrenal production of
dehydroepiandrosterone
• Other hormonal secretions change with age but changes are less constant and defined
• Actions of some hormones decrease with aging. In response to a lower sensitivity of
peripheral tissue, hormonal secretion may or may not increase
• Most clinically significant changes take place in carbohydrate metabolism, with
decrease in pancreatic secretion of insulin and increase in insulin peripheral resistance,
as well as in the thyroid (hypothyroidism of autoimmune origin)
SELECTED REFERENCES
2. Snyder PJ. Approach to older men with low testosterone. Uptodate. www.uptodate.com. Last
updated: May 2018. Accessed: March 2019.
3. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical
Practice Guideline. J Clin Endocrinol Metab 103: 1715–1744, 2018.
4. Endocrine Society statement on the risk of cardiovascular events in men receiving testosterone
therapy. https://www.endocrine.org/membership/email-newsletters/endocrine-insider/2014/
february-20-2014/society-statement-risk-of-cardiovascular-events-in-men-receiving-
testosterone-therapy-available.
5. Commitee of Institute of Medicine. National Academy Press, 2014.
6. Rudman D et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1–
6, 1990.
7. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and
men: a randomized controlled trial. JAMA 288: 2282–2292, 2002.
8. Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann
Intern Med 146: 104–115, 2007.
9. Attanasio AF et al. Human Growth Hormone replacement in adult hypopituitary patients: long-term
effects on body composition and lipid status—3-year results from the HypoCCS Database. J Clin
Endocrinol Metab 87: 1600–1606, 2002.
10. Bartke A et al. Life extension in the dwarf mouse. Curr Top Dev Biol 63: 189–225, 2004.
11. Coschigano KT, et al. Assessment of growth parameters and life span of GHR/BP gene-disrupted
mice. Endocrinology 141: 2608–2613, 2000.
12. Stuenkel et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab 100: 3975–4011, 2015.
13. Writing Group for the Women’s Health Initiative Investigators. JAMA 288: 321–333, 2002.
14. Manson JE et al. Menopausal hormone therapy and health outcomes during the intervention and
extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:
1353–1368, 2013.
15. Grady D. HERS study. JAMA 288: 49–57, 2002.
16. Martin KA, Barbieri RL. Menopausal hormone therapy: Benefits and risks. Uptodate. www.
uptodate.com. Last update: August 2018. Accessed: April 2019.
17. Harman SM. Endocrine changes with aging. Uptodate. Last updated: November 2016. Accessed:
July 2017.
18. Nair KS et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl Med 355:
1647–1659, 2006.